Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.55 USD
-0.07 (-2.67%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.56 +0.01 (0.39%) 7:58 PM ET
5-Strong Sell of 5 5
B Value F Growth C Momentum D VGM
Organogenesis (ORGO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.38 | $6.00 | $3.00 | 67.18% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Organogenesis comes to $4.38. The forecasts range from a low of $3.00 to a high of $6.00. The average price target represents an increase of 67.18% from the last closing price of $2.62.
Analyst Price Targets (4 )
Broker Rating
Organogenesis currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Lake Street Capital Markets | Brooks G O'Neil | Not Available | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
12/27/2023 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $4.38 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | 0.01 |